Clinical Trial Detail

NCT ID NCT03589326
Title An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

acute lymphoblastic leukemia

Therapies

Cytarabine + Methotrexate + Ponatinib

Dexamethasone + Ponatinib + Vincristine Sulfate

Ponatinib + Prednisone + Vincristine Sulfate

Dexamethasone + Imatinib + Vincristine Sulfate

Cytarabine + Imatinib + Methotrexate

Imatinib + Prednisone + Vincristine Sulfate

Age Groups: senior adult

No variant requirements are available.